[{"id":"6abdabcb-20ec-463a-9da6-da3f3fef4258","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502330","created_at":"2021-01-18T17:14:06.052Z","updated_at":"2025-02-25T14:26:50.517Z","phase":"Phase 1","brief_title":"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma","source_id_and_acronym":"NCT03502330","lead_sponsor":"Yale University","biomarkers":" PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (PYX-107)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/09/2018","start_date":" 06/09/2018","primary_txt":" Primary completion: 01/05/2022","primary_completion_date":" 01/05/2022","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-07-03"},{"id":"9a21ddef-5b64-4557-9763-3d868208cdc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04331067","created_at":"2021-01-18T20:58:28.227Z","updated_at":"2025-02-25T14:29:13.075Z","phase":"Phase 1/2","brief_title":"Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer","source_id_and_acronym":"NCT04331067","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • paclitaxel • cabiralizumab (BMS-986227)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/19/2020","start_date":" 11/19/2020","primary_txt":" Primary completion: 03/20/2023","primary_completion_date":" 03/20/2023","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-05-16"},{"id":"dfb86429-181f-4825-ac3d-e1a521a067ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03927105","created_at":"2021-01-18T19:20:59.843Z","updated_at":"2025-02-25T14:28:20.534Z","phase":"Phase 2","brief_title":"Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03927105","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2024-03-18"},{"id":"ed108878-46a5-4e3a-93b2-f64236ea023a","acronym":"C4-MOSART","url":"https://clinicaltrials.gov/study/NCT03431948","created_at":"2021-01-18T16:55:43.382Z","updated_at":"2025-02-25T14:38:06.135Z","phase":"Phase 1","brief_title":"Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer","source_id_and_acronym":"NCT03431948 - C4-MOSART","lead_sponsor":"University of Chicago","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • urelumab (BMS-663513)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 02/29/2020","primary_completion_date":" 02/29/2020","study_txt":" Completion: 04/11/2022","study_completion_date":" 04/11/2022","last_update_posted":"2023-02-16"}]